GlaxoSmithKline Pharmaceuticals Limited announced its financial results for the second quarter ended June 30, 2012. The growth in Net Sales was 16% and Profit After Tax and before Exceptional Items was 12%. The core Pharmaceuticals business grew by 16.3% for the quarter.

The quarter saw a growth across all the business verticals. Dermatology and Vaccines continued to grow strongly. Despite material cost escalations and adverse exchange rate movement, the EBITDA margin was 33% for the quarter.

In the Second quarter, the Company launched Uricostat for Gout treatment. The Company expanded its Oncology portfolio by launching Hycamtin™ to fulfil unmet needs for patients with advance cancers and relapsed small cell lung cancer (SCLC).

The company also introduced Volibris (Ambrisentan), a non-sulphonamide class endothelin receptor antagonist (ERA) used to treat pulmonary arterial hypertension (PAH).

During the quarter, a Metered Dose Inhaler (MDI) with dose counter was launched, which will help patients keep a correct count of drug doses taken. This technology has been introduced in Seretide® Evohaler®.

Commenting on the performance, Dr. Hasit B. Joshipura, Managing Director, said, “Growth for the quarter was market competitive, with all the segments delivering strong growth.”

**About GlaxoSmithKline:**

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world’s leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com.

**For enquiries, please contact:**

Nandini Goswami
General Manager, Corporate Communications

+91 22 24959203
nandini.x.goswami@gsk.com